Collaboration Tool Investors
CapLink currently tracks 6 verified investors focused on Collaboration Tool — a small but growing slice of the global funding landscape.
The mix is led by VC, Corporate VC and Incubator, Accelerator. Deal coverage spans Pre-Seed through Series B, with the largest concentration at Seed.
Investor headquarters cluster in United States, Canada, Antigua and Barbuda, Barbados and Belize, with activity across 26 countries in total. Ticket sizes range from roughly $30K to $10M, covering early angel cheques through to growth-stage rounds.
Use the pre-filtered database below to explore every Collaboration Tool investor on CapLink, or sign up to unlock contact details, ticket sizes and detailed investment criteria.
Collaboration Tool investor database
6 investors matched for Collaboration Tool. Sign up to unlock contact details and full profiles.
| Investor |
|---|
AngelMD AngelMD is an online community dedicated to healthcare innovation, connecting clinicians, startups, and investors to address pressing healthcare challenges. The platform offers resources for physicians and dentists to engage with new technologies and startups, fostering collaboration and learning. Startups benefit from a community of clinicians and tools to optimize their ventures, while investors gain access to private healthcare transactions.
AngelMD emphasizes the power of social collaboration in driving healthcare innovation. |
Trust Fund Trust Fund is a venture capital firm specializing in pre-seed and seed, early venture, and growth capital investments. The firm seeks to invest in marketing, productivity, project management, collaboration, marketplaces, e-commerce enablement, artificial intelligence, B2B, supply chain optimization, people management, the creator economy, the freelance/creator/gig economy, fintech, sales tools, and CRM. The invests $0.15 million and $0.3 million in pre-seed and seed stage companies. Trust Fund was founded in 2022 and is based in Los Angeles, California. |
P1 Ventures P1 Ventures is a venture capital firm specializing in startups, growth capital, early stage investments and seed capital. The firm typically considers investments in industrial technology; fintech, energy technologies including power generation and consumption and oil and gas; advanced manufacturing including smart factories, collaboration, design tools, advanced fabrication, automation, and robotics; industrial productivity including software, analytics, industrial internet, safety, and quality sectors. The firm seeks to invest across Africa. P1 Ventures was founded in 2020 and is based in Grand Cayman, Cayman Islands with additional office in San Francisco, California |
Amgen Ventures Amgen Ventures is a venture capital arm of Amgen Inc. specializing in direct investments in early stage, seed/startup, growth capital, mid venture, later stage, and emerging companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, bone health, nephrology, metabolic disorders, neuroscience, and cardiovascular therapeutics. In oncology, it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care, including mucositis and cachexia. In nephrology, the firm focuses on renal failure and hyperparathyroidism. For inflammation, the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders, it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology, the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in Thousand Oaks, California; with additional offices in San Francisco, California; Seattle, Washington; and Cambridge, Massachusetts. |
Illumina Ventures Illumina Ventures is an independently managed venture capital firm specializing in genomics and precision health investments. Established in 2016, the firm focuses on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. Their strategic partnership with Illumina, Inc.
(NASDAQ: ILMN) provides access to the expertise and vision of the world's leading genomics solutions provider. This collaboration enables Illumina Ventures to identify and build companies that will transform healthcare and the world. The firm's investment areas include life science tools, diagnostics, therapeutics, digital health, and sustainability.
Through Illumina Ventures Labs, they offer capital, sequencing, mentorship, and fully equipped genomics lab capabilities to accelerate value creation for early-stage genomics startups. |
![]() Health Wildcatters Health Wildcatters is a Dallas-based, mentor-driven seed accelerator and fund dedicated to advancing healthcare innovation by supporting early-stage startups. Founded in 2013, the organization focuses on sectors such as IT, SaaS, digital and mobile health, medical devices, diagnostics, research tools, and pharmaceuticals. Health Wildcatters offers a comprehensive program that includes seed investment, in-kind perks, and access to a vast network of over 200 mentors spanning the healthcare industry and professional services.
Each year, 8 to 12 startups participate in a ten-week accelerator program from September to November, culminating in a pitch day. Since its inception, Health Wildcatters has expanded its portfolio to 109 startups, collectively raising over $250 million. The organization relocated to the Pegasus Park bioscience campus in Dallas in early 2022, providing over 6,000 square feet of collaborative and flexible office space to foster innovation and collaboration among healthcare startups.
In 2024, Health Wildcatters' "Women in Science and Healthcare" (WISH) initiative won a $50,000 prize from the U.S. Small Business Administration's Growth Accelerator Fund Competition, recognizing its impact on nurturing STEM-based entrepreneurship. This funding will expand the WISH Network, focusing on female entrepreneurs in healthcare and science, with over 250 participants already engaged.
Health Wildcatters continues to play a pivotal role in strengthening Dallas-Fort Worth's position as a growing hub for health tech and biotech innovation. |
Understanding Collaboration Tool investors
What are Collaboration Tool investors, and what do they look for?
Collaboration software has an adoption problem disguised as a product problem, and investors have learned to look past feature comparisons to the mechanics of how a tool spreads. The category is crowded, switching is disruptive because it affects everyone at once, and incumbents are deeply entrenched. What persuades investors is evidence that teams adopt without being mandated, and that adoption spreads from one team to another inside the same organisation. Engagement depth matters more than seat count. A tool that a licensed user opens weekly is a renewal risk regardless of contract value, so investors examine daily and weekly activity, actions per user and whether usage survives past the initial enthusiasm. The third question is the wedge. Broad collaboration platforms are effectively closed to newcomers, so successful companies enter through a specific workflow, function or profession and expand from there. Investors want to hear a narrow, defensible starting point and a credible account of what earns the right to expand, rather than an ambition to replace an incumbent suite.
Why Collaboration Tool is attracting investor interest
Distributed work stopped being temporary, and the tooling implications settled into something durable. Organisations that expected a return to previous arrangements have largely accepted hybrid patterns, which means the coordination problems created by people working in different places and time zones are permanent rather than transitional. Asynchronous working emerged as the more interesting commercial thread. Meeting-heavy cultures scale poorly across time zones, and tools that let work progress without everyone present address a problem that grows as organisations become more distributed. Investors find this more compelling than another synchronous communication product competing with entrenched incumbents. Consolidation pressure cuts both ways and shapes what gets funded. Buyers are actively reducing the number of tools they pay for, which is difficult for point solutions and helpful for anything that replaces several products at once. European data protection requirements create a persistent opening, since collaboration tools process substantial personal data and communications, and organisations in regulated sectors and the public sector need providers who can satisfy residency and processing obligations that global incumbents sometimes cannot.
Which funding stages Collaboration Tool investors are active at
Collaboration companies typically raise on adoption metrics before meaningful revenue, and investors accept that when the spread is genuine. Seed rounds fund product and early team adoption, with investors reading engagement rather than contract value. Bottom-up distribution is the norm, and a product that requires a sales conversation to get its first users faces scepticism. Series A demands the transition from team adoption to organisational contracts, which is where most companies in this category stall. Investors want evidence that individual team usage converted into a company-wide purchase with a procurement process behind it, since revenue built on many small team subscriptions is fragile and expensive to service. Series B and later focus on expansion within accounts and on resistance to consolidation. Investors examine whether the product has become embedded in a workflow or remains a convenience that could be cut in a tooling review. Growth capital is available for companies showing strong net retention, and strategic acquirers include the large productivity suite vendors, which is the most common outcome for successful European companies in this space.
Types of investors active in Collaboration Tool
Funds specialising in bottom-up software adoption, reading activation, engagement depth and organic team-to-team spread. They are the natural early backers here and the most rigorous about whether adoption converts into enterprise contracts.
Investors focused on how organisations operate, who understand the shift towards distributed and asynchronous working. They evaluate against workflow change rather than feature parity and are more receptive to narrow wedges than generalists.
Later-stage capital underwriting retention and account expansion. They engage only once organisational contracts exist, and they treat suite consolidation as the central risk in their analysis.
Strategic arms of the large vendors whose suites your product sits alongside. They offer marketplace distribution and integration, and they are the most likely acquirers, with the accompanying risk of native replication.
Funds backing collaboration tools built for a specific profession, such as engineering, design, legal or clinical teams. Domain specificity is the practical defence against horizontal incumbents, and these investors understand that trade-off.
Ready to reach Collaboration Tool investors?
Create a free CapLink account to unlock full investor profiles, contact details, ticket sizes and intelligent matching.
